TY - JOUR
T1 - The Association Between Conversion to In-centre Nocturnal Hemodialysis and Left Ventricular Mass Regression in Patients With End-Stage Renal Disease
AU - Wald, Ron
AU - Goldstein, Marc B.
AU - Perl, Jeffrey
AU - Kiaii, Mercedeh
AU - Yuen, Darren
AU - Wald, Rachel M.
AU - Harel, Ziv
AU - Weinstein, Jordan J.
AU - Jakubovic, Baruch
AU - Leong-Poi, Howard
AU - Kirpalani, Anish
AU - Leipsic, Jonathon
AU - Dacouris, Niki
AU - Wolf, Myles
AU - Yan, Andrew T.
N1 - Funding Information:
This study was supported by an operating grant from the Canadian Institutes of Health Research. The study sponsor had no role in the study design, data collection or analysis, interpretation of the findings, writing the manuscript, or the decision to submit the manuscript for publication. ClinicalTrials.gov Identifier: NCT00718848 .
Publisher Copyright:
© 2016 Canadian Cardiovascular Society.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background: In-centre nocturnal hemodialysis (INHD, 7-8 hours/session, 3 times/week) is an increasingly utilized form of dialysis intensification, though data on the cardiovascular benefits of this modality are limited. Methods: In this prospective cohort study, we enrolled 67 prevalent conventional hemodialysis (CHD, 4 hours/session, 3 times/week) recipients at 2 medical centres in Canada, of whom 37 converted to INHD and 30 remained on CHD. The primary outcome was the change in left ventricular mass (LVM) after 1 year as assessed by cardiac magnetic resonance imaging. Secondary outcomes included changes in serum phosphate concentration, phosphate binder burden, haemoglobin, erythropoiesis stimulating agent usage, and blood pressure. Results: Conversion to INHD was associated with a 14.2 (95% confidence interval [CI] 1.2-27.2) g reduction in LVM as compared with continuation on CHD. This result was maintained after adjustment for baseline imbalances between the groups and in ancillary analyses. There was a trend toward a larger drop in systolic blood pressure (9.8 [95% CI, -1.4-20.9] mm Hg) among INHD recipients with a significant reduction in the number of prescribed antihypertensive agents (0.7 [95% CI, 0.3-1.1] agents). Serum phosphate declined by 0.40 (95% CI, 0.16-0.63) mmol/L among INHD recipients without any difference in calcium-based phosphate binder requirements, as compared with those who remained on CHD. Conclusions: Compared with continuation of CHD, conversion to INHD was associated with significant LVM regression and reduction in serum phosphate concentration at 1 year.
AB - Background: In-centre nocturnal hemodialysis (INHD, 7-8 hours/session, 3 times/week) is an increasingly utilized form of dialysis intensification, though data on the cardiovascular benefits of this modality are limited. Methods: In this prospective cohort study, we enrolled 67 prevalent conventional hemodialysis (CHD, 4 hours/session, 3 times/week) recipients at 2 medical centres in Canada, of whom 37 converted to INHD and 30 remained on CHD. The primary outcome was the change in left ventricular mass (LVM) after 1 year as assessed by cardiac magnetic resonance imaging. Secondary outcomes included changes in serum phosphate concentration, phosphate binder burden, haemoglobin, erythropoiesis stimulating agent usage, and blood pressure. Results: Conversion to INHD was associated with a 14.2 (95% confidence interval [CI] 1.2-27.2) g reduction in LVM as compared with continuation on CHD. This result was maintained after adjustment for baseline imbalances between the groups and in ancillary analyses. There was a trend toward a larger drop in systolic blood pressure (9.8 [95% CI, -1.4-20.9] mm Hg) among INHD recipients with a significant reduction in the number of prescribed antihypertensive agents (0.7 [95% CI, 0.3-1.1] agents). Serum phosphate declined by 0.40 (95% CI, 0.16-0.63) mmol/L among INHD recipients without any difference in calcium-based phosphate binder requirements, as compared with those who remained on CHD. Conclusions: Compared with continuation of CHD, conversion to INHD was associated with significant LVM regression and reduction in serum phosphate concentration at 1 year.
UR - http://www.scopus.com/inward/record.url?scp=84959493178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959493178&partnerID=8YFLogxK
U2 - 10.1016/j.cjca.2015.07.004
DO - 10.1016/j.cjca.2015.07.004
M3 - Article
C2 - 26386732
AN - SCOPUS:84959493178
SN - 0828-282X
VL - 32
SP - 369
EP - 377
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 3
ER -